Connection

M ATASSI to Molecular Sequence Data

This is a "connection" page, showing publications M ATASSI has written about Molecular Sequence Data.
Connection Strength

2.282
  1. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.085
  2. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin. Immunobiology. 2014 Dec; 219(12):950-7.
    View in: PubMed
    Score: 0.077
  3. Location of the synaptosome-binding regions on botulinum neurotoxin B. Biochemistry. 2012 Jan 10; 51(1):316-28.
    View in: PubMed
    Score: 0.064
  4. Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A. Immunol Lett. 2012 Feb 29; 142(1-2):20-7.
    View in: PubMed
    Score: 0.064
  5. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients. Autoimmunity. 2012 Mar; 45(2):153-60.
    View in: PubMed
    Score: 0.063
  6. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Immunobiology. 2012 Jan; 217(1):1-7.
    View in: PubMed
    Score: 0.063
  7. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.063
  8. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
    View in: PubMed
    Score: 0.060
  9. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin. Immunobiology. 2011 Jun; 216(6):698-706.
    View in: PubMed
    Score: 0.059
  10. Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions. Protein J. 2010 Jul; 29(5):320-7.
    View in: PubMed
    Score: 0.058
  11. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Toxicon. 2009 Oct; 54(5):600-13.
    View in: PubMed
    Score: 0.053
  12. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.051
  13. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol. 2008 Feb; 45(4):910-24.
    View in: PubMed
    Score: 0.048
  14. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
    View in: PubMed
    Score: 0.046
  15. Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action. Crit Rev Immunol. 2007; 27(4):319-41.
    View in: PubMed
    Score: 0.046
  16. Targeting the antigen-binding site of HLA-restricting alleles in treatment of autoimmune disease. Crit Rev Immunol. 2007; 27(3):271-88.
    View in: PubMed
    Score: 0.046
  17. Subtle differences in HLA DQ haplotype-associated presentation of AChR alpha-chain peptides may suffice to mediate myasthenia gravis. Autoimmunity. 2006 Jun; 39(4):277-88.
    View in: PubMed
    Score: 0.044
  18. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
    View in: PubMed
    Score: 0.043
  19. Use of alum and inactive Bordetella pertussis for generation of antibodies against synthetic peptides in mice. Immunol Invest. 2006; 35(2):137-48.
    View in: PubMed
    Score: 0.043
  20. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol. 2005 Aug; 42(12):1509-20.
    View in: PubMed
    Score: 0.040
  21. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor alpha-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity. Hum Immunol. 2005 Jan; 66(1):32-42.
    View in: PubMed
    Score: 0.040
  22. Oxygen-binding heme complexes of peptides designed to mimic the heme environment of myoglobin and hemoglobin. Protein J. 2005 Jan; 24(1):37-49.
    View in: PubMed
    Score: 0.040
  23. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest. 2005; 34(2):119-42.
    View in: PubMed
    Score: 0.040
  24. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 2004 Jan; 23(1):39-52.
    View in: PubMed
    Score: 0.037
  25. Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity. 2002 May; 35(3):183-90.
    View in: PubMed
    Score: 0.033
  26. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. Crit Rev Immunol. 2001; 21(1-3):1-27.
    View in: PubMed
    Score: 0.030
  27. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J Neuroimmunol. 2000 Jun 26; 105(2):131-44.
    View in: PubMed
    Score: 0.029
  28. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of Myasthenia gravis? Hum Immunol. 2000 Mar; 61(3):255-65.
    View in: PubMed
    Score: 0.028
  29. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol. 1999; 19(3):219-60.
    View in: PubMed
    Score: 0.026
  30. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol Lett. 1998 Jan; 60(1):7-12.
    View in: PubMed
    Score: 0.024
  31. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products. Autoimmunity. 1998; 27(2):79-90.
    View in: PubMed
    Score: 0.024
  32. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol Immunol. 1997 Oct; 34(14):1031-40.
    View in: PubMed
    Score: 0.024
  33. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest. 1997 Jun; 26(4):491-504.
    View in: PubMed
    Score: 0.023
  34. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides. Crit Rev Immunol. 1997; 17(5-6):481-95.
    View in: PubMed
    Score: 0.023
  35. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol. 1996 Oct 01; 157(7):3192-9.
    View in: PubMed
    Score: 0.022
  36. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem. 1996 Oct; 15(7):691-700.
    View in: PubMed
    Score: 0.022
  37. Protection against alpha-bungarotoxin poisoning by immunization with synthetic toxin peptides. Mol Immunol. 1996 May-Jun; 33(7-8):681-9.
    View in: PubMed
    Score: 0.022
  38. Antibody and T-cell recognition of alpha-bungarotoxin and its synthetic loop-peptides. Mol Immunol. 1995 Aug; 32(12):919-29.
    View in: PubMed
    Score: 0.021
  39. Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin. Vaccine. 1995 Jul; 13(10):927-32.
    View in: PubMed
    Score: 0.021
  40. Effect of amino acid substitutions within the region 62-76 of I-A beta b on binding with and antigen presentation of Torpedo acetylcholine receptor alpha-chain peptide 146-162. J Immunol. 1995 May 15; 154(10):5245-54.
    View in: PubMed
    Score: 0.020
  41. Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Adv Exp Med Biol. 1995; 383:141-56.
    View in: PubMed
    Score: 0.020
  42. Analysis of exposed regions on the main extracellular domain of mouse acetylcholine receptor alpha subunit in live muscle cells by binding profiles of antipeptide antibodies. J Protein Chem. 1994 Nov; 13(8):715-22.
    View in: PubMed
    Score: 0.020
  43. Profile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol Immunol. 1994 Aug; 31(11):833-43.
    View in: PubMed
    Score: 0.019
  44. Mapping of the polypeptide chain organization of the main extracellular domain of the alpha-subunit in membrane-bound acetylcholine receptor by antipeptide antibodies spanning the entire domain. Adv Exp Med Biol. 1994; 347:221-8.
    View in: PubMed
    Score: 0.019
  45. Molecular recognition of acetylcholine receptor. Recognition by alpha-neurotoxins and by immune and autoimmune responses and manipulation of the responses. Adv Neuroimmunol. 1994; 4(4):403-32.
    View in: PubMed
    Score: 0.019
  46. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance. Adv Exp Med Biol. 1994; 347:65-75.
    View in: PubMed
    Score: 0.019
  47. Mapping the extracellular topography of the alpha-chain in free and in membrane-bound acetylcholine receptor by antibodies against overlapping peptides spanning the entire extracellular parts of the chain. J Protein Chem. 1994 Jan; 13(1):37-47.
    View in: PubMed
    Score: 0.019
  48. Biological activities of rat antisera raised against synthetic peptides of human thyrotropin receptor. Endocr J. 1993 Oct; 40(5):607-12.
    View in: PubMed
    Score: 0.018
  49. Design of peptide enzymes (pepzymes): surface-simulation synthetic peptides that mimic the chymotrypsin and trypsin active sites exhibit the activity and specificity of the respective enzyme. Proc Natl Acad Sci U S A. 1993 Sep 01; 90(17):8282-6.
    View in: PubMed
    Score: 0.018
  50. Amino acid substitutions outside a preselected antigenic region in hemoglobin affect the binding to monoclonal antibodies obtained by immunization with the synthetic region. J Protein Chem. 1993 Aug; 12(4):403-12.
    View in: PubMed
    Score: 0.018
  51. Autoimmune T-cell recognition sites of human thyrotropin receptor in Graves' disease. Mol Cell Endocrinol. 1993 Mar; 92(1):77-82.
    View in: PubMed
    Score: 0.017
  52. Profile of the regions on the alpha-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis. Mol Immunol. 1992 Dec; 29(12):1507-14.
    View in: PubMed
    Score: 0.017
  53. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 113-120 (antigenic site 4) of myoglobin. J Protein Chem. 1992 Dec; 11(6):677-86.
    View in: PubMed
    Score: 0.017
  54. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 145-151 (antigenic site 5) of myoglobin. J Protein Chem. 1992 Dec; 11(6):687-98.
    View in: PubMed
    Score: 0.017
  55. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin. J Protein Chem. 1992 Oct; 11(5):433-44.
    View in: PubMed
    Score: 0.017
  56. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 15-22 (antigenic site 1) of myoglobin. J Protein Chem. 1992 Oct; 11(5):445-54.
    View in: PubMed
    Score: 0.017
  57. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 56-62 (antigenic site 2) of myoglobin. J Protein Chem. 1992 Oct; 11(5):455-65.
    View in: PubMed
    Score: 0.017
  58. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):5852-6.
    View in: PubMed
    Score: 0.017
  59. HIV envelope protein is recognized as an alloantigen by human DR-specific alloreactive T cells. Hum Immunol. 1992 May; 34(1):31-8.
    View in: PubMed
    Score: 0.016
  60. Biological activities of rabbit antibodies against synthetic human thyrotropin receptor peptides representing thyrotropin binding regions. Biochem Biophys Res Commun. 1992 Feb 14; 182(3):1369-75.
    View in: PubMed
    Score: 0.016
  61. Synthesis of tolerogenic monomethoxypolyethylene glycol and polyvinyl alcohol conjugates of peptides. J Protein Chem. 1991 Dec; 10(6):623-7.
    View in: PubMed
    Score: 0.016
  62. Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):3613-7.
    View in: PubMed
    Score: 0.015
  63. The short-neurotoxin-binding regions on the alpha-chain of human and Torpedo californica acetylcholine receptors. Biochem J. 1991 Mar 15; 274 ( Pt 3):849-54.
    View in: PubMed
    Score: 0.015
  64. Autoimmune recognition profile of the alpha chain of human acetylcholine receptor in myasthenia gravis. Adv Exp Med Biol. 1991; 303:255-61.
    View in: PubMed
    Score: 0.015
  65. Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the alpha-chain of human hemoglobin. J Protein Chem. 1990 Dec; 9(6):735-42.
    View in: PubMed
    Score: 0.015
  66. Acetylcholine receptor-alpha-bungarotoxin interactions: determination of the region-to-region contacts by peptide-peptide interactions and molecular modeling of the receptor cavity. Proc Natl Acad Sci U S A. 1990 Aug; 87(16):6156-60.
    View in: PubMed
    Score: 0.015
  67. HLA-DR peptide inhibits HIV-induced syncytia. Immunol Lett. 1990 May; 24(2):127-31.
    View in: PubMed
    Score: 0.014
  68. Localization and synthesis of an insulin-binding region on human insulin receptor. J Protein Chem. 1990 Apr; 9(2):229-33.
    View in: PubMed
    Score: 0.014
  69. DR beta peptides block the antigen-specific response but not the alloresponse of a dual-reactive T-cell clone. Immunol Lett. 1990 Mar-Apr; 24(1):43-7.
    View in: PubMed
    Score: 0.014
  70. Generation of species-specific antihemoglobin antibodies by immunization with synthetic peptides of human hemoglobin. J Protein Chem. 1989 Dec; 8(6):767-78.
    View in: PubMed
    Score: 0.014
  71. Antigen presentation by non-immune B-cell hybridoma clones: presentation of synthetic antigenic sites reveals clones that exhibit no specificity and clones that present only one epitope. Immunol Invest. 1989 Oct; 18(8):987-92.
    View in: PubMed
    Score: 0.014
  72. Comparison of peptide-coating conditions in solid phase plate assays for detection of anti-peptide antibodies. Immunol Invest. 1989 Aug; 18(7):841-51.
    View in: PubMed
    Score: 0.014
  73. Alloreactive T cell recognition of the HLA-DR beta N-terminal polymorphic region. Immunol Lett. 1989 Jun 15; 21(4):285-90.
    View in: PubMed
    Score: 0.014
  74. Conformation-dependent recognition of a protein by T cells requires presentation without processing. Biochem J. 1989 May 01; 259(3):731-5.
    View in: PubMed
    Score: 0.013
  75. Mapping by synthetic peptides of the binding sites for acetylcholine receptor on alpha-bungarotoxin. J Protein Chem. 1988 Oct; 7(5):655-66.
    View in: PubMed
    Score: 0.013
  76. Molecular recognition of human insulin receptor by autoantibodies in a human serum. Immunol Invest. 1988 May; 17(3):237-42.
    View in: PubMed
    Score: 0.012
  77. The regions of alpha-neurotoxin binding on the extracellular part of the alpha-subunit of human acetylcholine receptor. J Protein Chem. 1988 Apr; 7(2):173-7.
    View in: PubMed
    Score: 0.012
  78. T-cell recognition of lysozyme. I. Localization of regions stimulating T-cell proliferative response by synthetic overlapping peptides encompassing the entire molecule. Exp Clin Immunogenet. 1984; 1(2):99-111.
    View in: PubMed
    Score: 0.009
  79. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. Clin Immunol Immunopathol. 1993 Mar; 66(3):230-8.
    View in: PubMed
    Score: 0.004
  80. Characteristics of peptides which compete for presented antigen-binding sites on antigen-presenting cells. Eur J Immunol. 1990 May; 20(5):953-60.
    View in: PubMed
    Score: 0.004
  81. A Vh region synthetic peptide induces antibodies which bind native immunoglobulins and augment an immune response to antigen. Adv Exp Med Biol. 1989; 251:129-43.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.